Restrictive Use of Restraints and Delirium Duration in ICU
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 423 people enrolled
- Started
- 25 Jan 2021
- Ended
- 8 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Systematic use group
- Restrictive use group
- Record updated
- 23 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patients fulfilling all the following criteria will be eligible:
- Adults ≥ 18 years
- MV expected for at least ≥ 48 hours
- Invasive MV in the ICU for a duration inferior to 6 hours
- eligible to prescription for physical contention
Who cannot take part
- Documented delirium prior to ICU admission according to the CAM-ICU
- History of dementia (Mini mental test < 24)
- Alcoholic withdrawal syndrome expected
- Admission for any neurological disease including post-cardiopulmonary resuscitation (including cardiac arrest, stroke, traumatic brain injury, meningoencephalitis, and status epilepticus)
- Serious auditory or visual disorders
- Patients meeting one of the following criteria will not be considered for inclusion:
- Unable to understand French
- Pregnant or lactating women
- SAPS II > 65 points at screening
- Do-not-resuscitate orders (advance directives)
- No affiliation to a social security regime (beneficiary or assignee)
- Patient or person of confidence (if present at the time of inclusion) opposing the patient's participation in research
- Patient already involved in another interventional clinical research whose main objective is related to delirium
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The R2D2-ICU study will be a prospective, parallel-group, open label, multicenter (6 centers) randomized controlled trial. All consecutive eligible patients will be included. Patients will be randomly assigned (1/1 ratio) to either systematic PR use (systematic use group) or restrictive PR use (restrictive use group). Patients in the restrictive PR group will be subjected to PR only in case of severe agitation defined by a RASS ≥ +3. Physical restraint will consist of wrist straps. In both groups, patients will receive standardized management for analgesia, sedation, delirium detection, weaning and early mobilization according to current guidelines. Concealment will be obtained using a computer-generated randomization scheme of various-sized blocks stratified by center, age (< or ≥ 65 years) and coma at the beginning of invasive mechanical ventilation (D0)) through a centralized 24h/24h internet service. Investigation blinded to group assignment is not feasible. In both arms, patients' arousal will be evaluated twice a day until day 14 with the use of RASS. Patients with a RASS of -5 or -4 will be considered comatose (and will not be assessed for delirium). Patients with a RASS score ≥ -3 will be assessed for delirium with the use of the CAM-ICU scale twice a day.
The 2 groups in the trial
- Systematic use groupExisting treatment, for comparison
- Restrictive use groupTreatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Restrictive Use of Restraints and Delirium Duration in ICU: a Randomized Controlled Trial
- Publications
- Restrictive vs Liberal Physical Restraint Strategies in Critically Ill Patients: The R2D2-ICU Randomized Clinical Trial.JAMA, 2026
- Restrictive use of Restraints and Delirium Duration in the Intensive Care Unit (R2D2-ICU): protocol for a French multicentre parallel-group open-label randomised controlled trial.BMJ open, 2024
- Record updated
- 23 March 2026